Testing Modified Versions of the Matrixyl Skincare Peptide for Safety and Collagen-Boosting Potential

Researchers designed and synthesized a series of pentapeptides based on the KTTKS sequence, modifying them with acetyl, lipoyl, or palmitoyl groups. They tested each analogue's ability to inhibit six proteases (urokinase, thrombin, trypsin, plasmin, t-PA, and kallikrein). Cytotoxicity was assessed on cultured fibroblasts, and selected peptides were further tested for their effects on collagen and DNA biosynthesis.

KTTKS (marketed as Matrixyl®) is one of the most widely used peptides in anti-aging skincare. This study explored whether chemical modifications to the KTTKS backbone could improve its stability or biological activity. The finding that palmitoyl versions were strong plasmin inhibitors is notable because plasmin breaks down extracellular matrix proteins — blocking it could theoretically help preserve collagen in skin. The lack of cytotoxicity across all analogues is reassuring for potential topical applications.

As the cosmetic peptide market grows, researchers are looking for ways to improve on first-generation ingredients like Matrixyl®. This study adds to a growing body of work exploring how chemical modifications can enhance peptide stability and biological activity. The plasmin-inhibiting properties of the palmitoyl analogues suggest a dual mechanism — not just stimulating new collagen production, but also protecting existing collagen from enzymatic breakdown.

This was an in vitro study using cultured fibroblasts, so results may not translate to intact human skin. The peptides that promoted cell growth did not show dose-response relationships in collagen/DNA synthesis assays, making it hard to determine optimal concentrations. No skin penetration or in vivo testing was performed.